Alexander "Bo" Cumbo is the President and CEO of Solid Biosciences Inc., a biotech firm focused on advancing treatments for Duchenne muscular dystrophy. He joined the company in late 2022, bringing a wealth of experience from various leadership roles in...
Alexander "Bo" Cumbo is the President and CEO of Solid Biosciences Inc., a biotech firm focused on advancing treatments for Duchenne muscular dystrophy. He joined the company in late 2022, bringing a wealth of experience from various leadership roles in the biotech sector, including positions at Sarepta Therapeutics and Vertex Pharmaceuticals. A graduate of Auburn University with a degree in Laboratory Technology, Cumbo has spent nearly two decades in the industry, focusing on commercial strategies and product development. His insider trading history shows significant investments in Solid Biosciences, including sales peaking at over $8 million in mid-2020, indicating a strong personal stake in the company’s success. In 2023, Cumbo received a total compensation of $775,000, which highlights a performance-driven pay structure consistent with biotech industry norms. Also noteworthy is his commitment to shareowner alignment, as seen in his stock options and rewards tied to company performance. Cumbo also serves on the board of Verve Therapeutics, adding another layer to his leadership profile in the healthcare space.